Technology Overview

Joint fluid is a frequently tested body fluid, yet has been largely ignored as a diagnostic tool. Current blood tests that are used to diagnose joint diseases can be influenced by other ailments such as a common cold, or other systemic illnesses, because blood travels throughout the entire body. This often leaves doctors with vague and ambiguous results for joint disease diagnosis. The individual joints of the body are isolated compartments that provide a specific view of any disease that currently exists in the joint. By detecting local biomarkers (or proteins), which measure the body.s specific response to each unique disease, our tests provide a much clearer, undistorted picture of the condition of a joint. This dramatically reduces the potential for false positive or negative results that occur with blood tests that are currently considered the standard of care. Joint fluid is currently analyzed with culture and examination of crystals. There are no simple analytic assays for joint fluid analysis.

Our tests use a small sample of a patient.s joint fluid (called synovial fluid) to measure the presence of disease specific biomarkers. The presence of these biomarkers in elevated levels indicates that the patient is reacting to a specific joint disease and serves as a positive diagnosis. In CD Diagnostics. target market, immunoassay diagnostic tests offer several major advantages relative to alternative technologies including ease of use, speed, adaptability, point-of-care, and cost-effectiveness. So, whereas physicians currently use a panel of tests to subjectively diagnose joint disease and infection, CD Diagnostics will provide a single, cost effective, and rapid test with a definitive result.